LITESPARK-012
Adding belzutifan to first-line lenvatinib-pembrolizumab did not deliver, a reminder that later-line success does not guarantee first-line benefit.
Results presented at ASCO GU 2026 fell short of the trial's goals for the belzutifan-containing triplet versus the lenvatinib-pembrolizumab doublet. Belzutifan's role in RCC is therefore later line and adjuvant (LITESPARK-022), not first-line intensification.
Pages like this
not linked directly; found by shared links- TrialLITESPARK-022
Shares Belzutifan, Renal cell carcinoma, Pembrolizumab.
- TrialLEAP-002
Shares Lenvatinib, Pembrolizumab.
- TrialCLEAR (KEYNOTE-581)
Shares Lenvatinib, Renal cell carcinoma, Pembrolizumab.
- TrialLITESPARK-005
Shares Belzutifan, Renal cell carcinoma.
- IdeaBiomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)
Shares Belzutifan, Renal cell carcinoma, Pembrolizumab.
- TrialLEAP-012
Shares Lenvatinib, Pembrolizumab.
- PersonWilliam G. Kaelin Jr.
Shares Belzutifan, Renal cell carcinoma.
- TrialKEYNOTE-775 / Study 309
Shares Lenvatinib, Pembrolizumab.